Welcome to STN International! Enter x:x

LOGINID:ssspta1611sxp

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page URLs for STN Seminar Schedule - N. America
NEWS 2		"Ask CAS" for self-help around the clock
NEWS 3	May 12	EXTEND option available in structure searching
NEWS 4	May 12	Polymer links for the POLYLINK command completed in REGISTRY
NEWS 5	May 27	New UPM (Update Code Maximum) field for more efficient patent SDIs in CAplus
NEWS 6	May 27	CAplus super roles and document types searchable in REGISTRY
NEWS 7	Jun 28	Additional enzyme-catalyzed reactions added to CASREACT
NEWS 8	Jun 28	ANTE, AQUALINE, BIOENG, CIVILENG, ENVIROENG, MECHENG, and WATER from CSA now available on STN(R)
NEWS 9	Jul 12	BEILSTEIN enhanced with new display and select options, resulting in a closer connection to BABS
NEWS 10	Jul 30	BEILSTEIN on STN workshop to be held August 24 in conjunction with the 228th ACS National Meeting
NEWS 11	AUG 02	IFIPAT/IFIUDB/IFICDB reloaded with new search and display fields
NEWS 12	AUG 02	CAplus and CA patent records enhanced with European and Japan Patent Office Classifications
NEWS 13	AUG 02	STN User Update to be held August 22 in conjunction with the 228th ACS National Meeting
NEWS 14	AUG 02	The Analysis Edition of STN Express with Discover! (Version 7.01 for Windows) now available
NEWS 15	AUG 04	Pricing for the Save Answers for SciFinder Wizard within STN Express with Discover! will change September 1, 2004

NEWS EXPRESS	JULY 30 CURRENT WINDOWS VERSION IS V7.01, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 11 AUGUST 2004
NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS INTER	General Internet Information
NEWS LOGIN	Welcome Banner and News Items
NEWS PHONE	Direct Dial and Telecommunication Network Access to STN
NEWS WWW	CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 14:06:37 ON 25 AUG 2004

=> file reg
COST IN U.S. DOLLARS

	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 14:06:47 ON 25 AUG 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 24 AUG 2004 HIGHEST RN 732209-96-0
DICTIONARY FILE UPDATES: 24 AUG 2004 HIGHEST RN 732209-96-0

TSCA INFORMATION NOW CURRENT THROUGH MAY 21, 2004

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more information enter HELP PROP at an arrow prompt in the file or refer to the file summary sheet on the web at:
http://www.cas.org/ONLINE/DBSS/registryss.html

=>
Uploading C:\Program Files\Stnexp\Queries\10626198.str

L1 STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1 STR



G1 O,S
G2 H,Cb,Ak
G3 H,Cy,Hy,Ak
G4 Cy,Hy,Ak
G5 NH,NH2,Cy,Hy

Structure attributes must be viewed using STN Express query preparation.

```
=> s l1 sss full
FULL SEARCH INITIATED 14:07:15 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -   1134 TO ITERATE

100.0% PROCESSED    1134 ITERATIONS                          25 ANSWERS
SEARCH TIME: 00.00.01

L2           25 SEA SSS FUL L1

=> file caplus
COST IN U.S. DOLLARS                          SINCE FILE      TOTAL
                                                   ENTRY    SESSION
FULL ESTIMATED COST                               155.42     155.63

FILE 'CAPLUS' ENTERED AT 14:07:22 ON 25 AUG 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)
```



```
FILE COVERS 1907 - 25 Aug 2004  VOL 141 ISS 9
FILE LAST UPDATED: 24 Aug 2004  (20040824/ED)

  This file contains CAS Registry Numbers for easy and accurate
  substance identification.


=> s l2
L3           3 L2

=> d l3 fbib hitstr ans total
'ANS' IS NOT A VALID FORMAT FOR FILE 'CAPLUS'

The following are valid formats:

ABS --------- GI and AB
ALL --------- BIB, AB, IND, RE
APPS -------- AI, PRAI
BIB --------- AN, plus Bibliographic Data and PI table (default)
CAN --------- List of CA abstract numbers without answer numbers
CBIB -------- AN, plus Compressed Bibliographic Data
DALL -------- ALL, delimited (end of each field identified)
DMAX -------- MAX, delimited for post-processing
FAM --------- AN, PI and PRAI in table, plus Patent Family data
FBIB -------- AN, BIB, plus Patent FAM
```

IND --------- Indexing data
IPC --------- International Patent Classifications
MAX --------- ALL, plus Patent FAM, RE
PATS -------- PI, SO
SAM --------- CC, SX, TI, ST, IT
SCAN -------- CC, SX, TI, ST, IT (random display, no answer numbers;
SCAN must be entered on the same line as the DISPLAY,
e.g., D SCAN or DISPLAY SCAN)
STD --------- BIB, IPC, and NCL

IABS -------- ABS, indented with text labels
IALL -------- ALL, indented with text labels
IBIB -------- BIB, indented with text labels
IMAX -------- MAX, indented with text labels
ISTD -------- STD, indented with text labels

OBIB -------- AN, plus Bibliographic Data (original)
OIBIB ------- OBIB, indented with text labels

SBIB -------- BIB, no citations
SIBIB ------- IBIB, no citations

HIT --------- Fields containing hit terms
HITIND ------ IC, ICA, ICI, NCL, CC and index field (ST and IT)
containing hit terms
HITRN ------- HIT RN and its text modification
HITSTR ------ HIT RN, its text modification, its CA index name, and
its structure diagram
HITSEQ ------ HIT RN, its text modification, its CA index name, its
structure diagram, plus NTE and SEQ fields
FHITSTR ----- First HIT RN, its text modification, its CA index name, and
its structure diagram
FHITSEQ ----- First HIT RN, its text modification, its CA index name, its
structure diagram, plus NTE and SEQ fields
KWIC -------- Hit term plus 20 words on either side
OCC --------- Number of occurrence of hit term and field in which it occurs

To display a particular field or fields, enter the display field codes. For a list of the display field codes, enter HELP DFIELDS at an arrow prompt (=>). Examples of formats include: TI; TI,AU; BIB,ST; TI,IND; TI,SO. You may specify the format fields in any order and the information will be displayed in the same order as the format specification.

All of the formats (except for SAM, SCAN, HIT, HITIND, HITRN, HITSTR, FHITSTR, HITSEQ, FHITSEQ, KWIC, and OCC) may be used with DISPLAY ACC to view a specified Accession Number.
ENTER DISPLAY FORMAT (BIB):bib

L3 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2002:10473 CAPLUS
DN 136:69824
TI Preparation of heterocycle compounds as melanocortin receptor ligands
IN Carpino, Philip Albert; Cole, Bridget McCarthy; Morgan, Bradley Paul
PA Pfizer Products Inc., USA
SO PCT Int. Appl., 108 pp.
CODEN: PIXXD2
DT Patent
LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002000654	A1	20020103	WO 2001-IB995	20010531
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	EP 1294719	A1	20030326	EP 2001-934254	20010531
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	BR 2001011567	A	20030506	BR 2001-11567	20010531
	JP 2004501917	T2	20040122	JP 2002-505778	20010531
	US 2002072604	A1	20020613	US 2001-891026	20010625
	BG 107268	A	20030630	BG 2002-107268	20021112
	ZA 2002010277	A	20031219	ZA 2002-10277	20021219
	NO 2002006280	A	20021230	NO 2002-6280	20021230
PRAI	US 2000-214616P	P	20000628		
	WO 2001-IB995	W	20010531		

OS MARPAT 136:69824

RE.CNT 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2004 ACS on STN

AN 2001:885763 CAPLUS

DN 136:15253

TI Melanocortin receptor agonists, and preparation thereof, for therapeutic use

IN Bakshi, Raman Kumar; Nargund, Ravi P.; Ye, Zhixiong

PA Merck & Co., Inc., USA

SO PCT Int. Appl., 59 pp.
CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001091752	A1	20011206	WO 2001-US17014	20010525
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	EP 1289526	A1	20030312	EP 2001-939460	20010525
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	JP 2003534377	T2	20031118	JP 2001-587767	20010525
	US 2002004512	A1	20020110	US 2001-867309	20010529
	US 6376509	B2	20020423		
PRAI	US 2000-207918P	P	20000530		

```
     WO 2001-US17014      W     20010525
OS   MARPAT 136:15253
RE.CNT  1     THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
              ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3   ANSWER 3 OF 3  CAPLUS  COPYRIGHT 2004 ACS on STN
AN   2000:151487  CAPLUS
DN   132:203148
TI   Heterocycle-containing dipeptide compounds as growth hormone
     secretagogues, their preparation, compositions containing them, and their
     applications
IN   Carpino, Philip Albert
PA   Pfizer Products Inc., USA
SO   Jpn. Kokai Tokkyo Koho, 94 pp.
     CODEN: JKXXAF
DT   Patent
LA   Japanese
FAN.CNT 1
     PATENT NO.           KIND   DATE        APPLICATION NO.         DATE
     ---------------      ----   --------    --------------------    --------
PI   JP 2000072771         A2    20000307    JP 1999-234704          19990820
     JP 3486137            B2    20040113
     US 6358951            B1    20020319    US 1999-377326          19990818
     EP 995748             A1    20000426    EP 1999-306576          19990819
     EP 995748             B1    20040331
         R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
             IE, SI, LT, LV, FI, RO
     AT 263168             E     20040415    AT 1999-306576          19990819
     BR 9903870            A     20001003    BR 1999-3870            19990820
     MX 9907844            A     20000331    MX 1999-7844            19990823
     US 2002045622         A1    20020418    US 2001-989040          20011121
     US 6559150            B2    20030506
     US 2003130284         A1    20030710    US 2002-313495          20021206
     US 6686359            B2    20040203
PRAI US 1998-97502P        P     19980821
     US 1999-377326        A3    19990818
     US 2001-989040        A3    20011121
OS   MARPAT 132:203148


=> d l3 fbib hitstr abs total

L3   ANSWER 1 OF 3  CAPLUS  COPYRIGHT 2004 ACS on STN
AN   2002:10473  CAPLUS
DN   136:69824
TI   Preparation of heterocycle compounds as melanocortin receptor ligands
IN   Carpino, Philip Albert; Cole, Bridget McCarthy; Morgan, Bradley Paul
PA   Pfizer Products Inc., USA
SO   PCT Int. Appl., 108 pp.
     CODEN: PIXXD2
DT   Patent
LA   English
FAN.CNT 1
     PATENT NO.           KIND   DATE        APPLICATION NO.         DATE
     ---------------      ----   --------    --------------------    --------
PI   WO 2002000654         A1    20020103    WO 2001-IB995           20010531
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
             CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
             GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
```

LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT,
RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US,
UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

			US 2000-214616P	P	20000628
EP 1294719	A1	20030326	EP 2001-934254		20010531
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR					
			US 2000-214616P	P	20000628
			WO 2001-IB995	W	20010531
BR 2001011567	A	20030506	BR 2001-11567		20010531
			US 2000-214616P	P	20000628
			WO 2001-IB995	W	20010531
JP 2004501917	T2	20040122	JP 2002-505778		20010531
			US 2000-214616P	P	20000628
			WO 2001-IB995	W	20010531
US 2002072604	A1	20020613	US 2001-891026		20010625
			US 2000-214616P	P	20000628
BG 107268	A	20030630	BG 2002-107268		20021112
			US 2000-214616P	P	20000628
			WO 2001-IB995	W	20010531
ZA 2002010277	A	20031219	ZA 2002-10277		20021219
			US 2000-214616P	P	20000628
NO 2002006280	A	20021230	NO 2002-6280		20021230
			US 2000-214616P	P	20000628
			WO 2001-IB995	W	20010531

OS MARPAT 136:69824

IT **384345-15-7P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of heterocycle compds. as melanocortin receptor ligands and therapeutic agents for treatment of prevention of obesity, diabetes mellitus, male or female sexual dysfunction)

RN 384345-15-7 CAPLUS

CN 2(1H)-Isoquinolinecarboxylic acid, 3-[[[(1R)-1-[(4-chlorophenyl)methyl]-2-[2,3,3a,4,6,7-hexahydro-2-methyl-3-oxo-3a-(phenylmethyl)-5H-pyrazolo[4,3-c]pyridin-5-yl]-2-oxoethyl]amino]carbonyl]-3,4-dihydro-, 1,1-dimethylethyl ester, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **384345-14-6P 384345-16-8P 384345-17-9P**
384345-21-5P 384345-22-6P 384345-23-7P
384345-24-8P 384345-25-9P 384345-26-0P
384345-27-1P 384345-28-2P 384345-29-3P
384345-30-6P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of heterocycle compds. as melanocortin receptor ligands and therapeutic agents for treatment of prevention of obesity, diabetes mellitus, male or female sexual dysfunction)

RN 384345-14-6 CAPLUS
CN 3-Isoquinolinecarboxamide, N-[(1R)-1-[(4-chlorophenyl)methyl]-2-[2,3,3a,4,6,7-hexahydro-2-methyl-3-oxo-3a-(phenylmethyl)-5H-pyrazolo[4,3-c]pyridin-5-yl]-2-oxoethyl]-1,2,3,4-tetrahydro-, hydrochloride, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



●x HCl

RN 384345-16-8 CAPLUS
CN 3-Isoquinolinecarboxamide, N-[(1R)-1-[(4-chlorophenyl)methyl]-2-[2,3,3a,4,6,7-hexahydro-2-methyl-3-oxo-3a-(phenylmethyl)-5H-pyrazolo[4,3-c]pyridin-5-yl]-2-oxoethyl]-1,2,3,4-tetrahydro-, hydrochloride, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



●x HCl

RN 384345-17-9 CAPLUS
CN 3-Isoquinolinecarboxamide, N-[(1R)-1-[(4-chlorophenyl)methyl]-2-[(3aR)-2,3,3a,4,6,7-hexahydro-2-methyl-3-oxo-3a-(phenylmethyl)-5H-pyrazolo[4,3-c]pyridin-5-yl]-2-oxoethyl]-1,2,3,4-tetrahydro-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 384345-21-5 CAPLUS
CN 3-Isoquinolinecarboxamide, N-[(1R)-1-[(4-chlorophenyl)methyl]-2-[(3aR)-2,3,3a,4,6,7-hexahydro-2-methyl-3-oxo-3a-(phenylmethyl)-5H-pyrazolo[4,3-c]pyridin-5-yl]-2-oxoethyl]-1,2,3,4-tetrahydro-, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 384345-22-6 CAPLUS
CN 3-Isoquinolinecarboxamide, N-[(1R)-1-[(4-chlorophenyl)methyl]-2-[2,3,3a,4,6,7-hexahydro-3-oxo-3a-(phenylmethyl)-2-(2,2,2-trifluoroethyl)-5H-pyrazolo[4,3-c]pyridin-5-yl]-2-oxoethyl]-1,2,3,4-tetrahydro-, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 384345-23-7 CAPLUS
CN 3-Isoquinolinecarboxamide, N-[(1R)-1-[(4-chlorophenyl)methyl]-2-[(3aS)-2-ethyl-3a-[(4-fluorophenyl)methyl]-2,3,3a,4,6,7-hexahydro-3-oxo-5H-pyrazolo[4,3-c]pyridin-5-yl]-2-oxoethyl]-1,2,3,4-tetrahydro-, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 384345-24-8 CAPLUS
CN 3-Isoquinolinecarboxamide, N-[(1R)-1-[(4-chlorophenyl)methyl]-2-[(3aS)-2-ethyl-3a-[(4-fluorophenyl)methyl]-2,3,3a,4,6,7-hexahydro-3-oxo-5H-pyrazolo[4,3-c]pyridin-5-yl]-2-oxoethyl]-1,2,3,4-tetrahydro-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 384345-25-9 CAPLUS
CN 3-Isoquinolinecarboxamide, N-[(1R)-1-[(4-chlorophenyl)methyl]-2-[(3aS)-3a-[(4-chlorophenyl)methyl]-2-ethyl-2,3,3a,4,6,7-hexahydro-3-oxo-5H-pyrazolo[4,3-c]pyridin-5-yl]-2-oxoethyl]-1,2,3,4-tetrahydro-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 384345-26-0 CAPLUS
CN 3-Isoquinolinecarboxamide, N-[(1R)-1-[(4-chlorophenyl)methyl]-2-[(3aS)-3a-[(4-chlorophenyl)methyl]-2-ethyl-2,3,3a,4,6,7-hexahydro-3-oxo-5H-pyrazolo[4,3-c]pyridin-5-yl]-2-oxoethyl]-1,2,3,4-tetrahydro-, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 384345-27-1 CAPLUS
CN 3-Isoquinolinecarboxamide, N-[(1R)-1-[(4-chlorophenyl)methyl]-2-[(3aS)-2,3,3a,4,6,7-hexahydro-2-methyl-3-oxo-3a-(phenylmethyl)-5H-pyrazolo[4,3-c]pyridin-5-yl]-2-oxoethyl]-1,2,3,4-tetrahydro-, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 384345-28-2 CAPLUS
CN 3-Isoquinolinecarboxamide, N-[(1R)-1-[(4-chlorophenyl)methyl]-2-[(3aR)-3a-[(3-fluorophenyl)methyl]-2,3,3a,4,6,7-hexahydro-3-oxo-5H-pyrazolo[4,3-c]pyridin-5-yl]-2-oxoethyl]-1,2,3,4-tetrahydro-, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 384345-29-3 CAPLUS
CN 3-Isoquinolinecarboxamide, N-[(1R)-1-[(4-chlorophenyl)methyl]-2-[2,3,3a,4,6,7-hexahydro-3-oxo-3a-(phenylmethyl)-2-(2,2,2-trifluoroethyl)-5H-pyrazolo[4,3-c]pyridin-5-yl]-2-oxoethyl]-1,2,3,4-tetrahydro-, (3S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 384345-30-6 CAPLUS
CN 3-Isoquinolinecarboxamide, N-[(1R)-1-[(4-chlorophenyl)methyl]-2-[2,3,3a,4,6,7-hexahydro-3-oxo-3a-(2-pyridinylmethyl)-5H-pyrazolo[4,3-c]pyridin-5-yl]-2-oxoethyl]-1,2,3,4-tetrahydro-, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



GI



II

AB Compds. represented by formula HET-COCR3R4-NX4-CO(CR6R7)m-D [I; wherein m = 0, 1 or 2; HET = heterocyclyl; R3, R4 = H,, C1-8 alkyl, CH(R8)-aryl, -CH(R8)-heteroaryl, -C0-3 alkyl-C3-8 cycloalkyl (wherein the aryl or heteroaryl groups are optionally substituted by one or two groups; R8 = H, C1-8 alkyl, -C0-3 alkylaryl, -C0-3 alkylheteroaryl, -C3-6 cycloalkyl); R6, R7 = H, C1-6 alkyl, -C0-3 alkyl-aryl, -C0-3 alkyl-heteroaryl, -C0-3 alkyl-C3-8 cycloalkyl; or R6 and R7 together with the nitrogen atom to which they are attached form a 5- or 6-membered ring optionally containing an addnl. heteroatom selected from O, S, NR3; D = -C0-6 alkylamino-C(:NR7)-NR15R16, -C0-6 alkylaminopyridyl, -C0-6 alkylaminoimidazolyl, -C0-6 alkylaminothiazolyl, -C0-6 alkylaminopyrimidinyl, -C0-6 alkylaminopiperazinyl-R15, -C0-6 alkylmorpholinyl, etc. (wherein R15, R16 = H, -C1-6 alkyl, -C0-3 alkylaryl, -C0-3 alkylheteroaryl, or -C0-3 alkyl-C3-8 cycloalkyl, wherein the alkyl and aryl groups are optionally substituted with one or two groups); X4 = H or C1-6 alkyl or X4 is taken together with R4 and the nitrogen atom to which X4 is attached and the carbon atom to which R4 is attached and form a five to seven membered ring] are prepared Melanocortins are peptides derived from pro-opiomelanocortins (POMC) that bind to and activate G-protein coupled receptors (GPCR's) of the melanocortin receptor family and regulate a diverse number of physiol. processes including food intake., metabolism, and

thermogenesis as well as sexual dysfunction. These compds. I are useful for the treatment or prevention of disorders, diseases, or conditions responsive to the activation of melanocortin receptor including obesity, diabetes mellitus, male or female sexual dysfunction, erectile dysfunction, or disorders that cause reduction in appetite, or feeding behavior and/or body weight; for modulating appetite and metabolic rates; for acutely stimulating the appetite for the treatment of hepatic lipidosis, cachexia, and other pathologies resulting in/from inappropriate food intake and weight loss; for acutely stimulating the appetite of livestock for the treatment of ketosis, postpartum anestrus, and other metabolic and reproductive pathologies resulting in/from inappropriate food intake and weight loss; and for enhancing growth and survivability of neonates in livestock. Thus, esterification of N-Boc-L-Tic-OH with N-hydroxysuccinimide using Et3N and EDC in CH2Cl2 at room temperature for 4 h gave 3,4-Dihydro-1H-isoquinoline-2,3-(S)-dicarboxylic acid 2-tert-Bu ester 3-(2,5-dioxopyrrolidin-1-yl) ester which was condensed with D-p-chlorophenylalanine in the presence of Et3N in CH2Cl2 at room temperature overnight to give 3-(S)-[(R)-1-Carboxy-2-(4-chlorophenyl)ethylcarbamoyl]-3,4-dihydro-1H-isoquinoline-2-carboxylic acid tert-Bu ester. The latter compound was further condensed with 8a-(Pyridin-2-ylmethyl)-2-(2,2,2-trifluoroethyl)tetrahydroimidazo[1,5-a]pyrazine-1,3-dione using Et3N and EDC in CH2Cl2 at 0° for 5 h to give (S)-3-[(R)-1-(4-Chlorobenzyl)-2-[1,3-dioxo-8a-(pyridin-2-ylmethyl)-2-(2,2,2-trifluoroethyl)hexahydroimidazo[1,5-a]pyrazin-7-yl]-2-oxoethylcarbamoyl]-3,4-dihydro-1H-isoquinoline-2-carboxylic acid tert-Bu ester which was treated with a mixture of EtOH and concentrated HCl at 0° for 0.5 h to give (S)-1,2,3,4-Tetrahydroisoquinoline-3-carboxylic acid N-[(R)-1-(4-chlorobenzyl)-2-[1,3-dioxo-8a-(pyridin-2-ylmethyl)-2-(2,2,2-trifluoroethyl)hexahydroimidazo[1,5-a]pyrazin-7-yl]-2-oxoethyl]amide (II) hydrochloride which may be considered as a dipeptide analog hepterocycle amide, N-[N-(L-1,2,3,4-Tetrahydroisoquinoline-3-carbonyl)-D-p-chlorophenylalanyl]-1,3-dioxo-8a-(pyridin-2-ylmethyl)-2-(2,2,2-trifluoroethyl)hexahydroimidazo[1,5-a]pyrazine.

RE.CNT 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2001:885763 CAPLUS
DN 136:15253
TI Melanocortin receptor agonists, and preparation thereof, for therapeutic use
IN Bakshi, Raman Kumar; Nargund, Ravi P.; Ye, Zhixiong
PA Merck & Co., Inc., USA
SO PCT Int. Appl., 59 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2001091752	A1	20011206	WO 2001-US17014	20010525

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,

BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
US 2000-207918P P 20000530
EP 1289526 A1 20030312 EP 2001-939460 20010525
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
US 2000-207918P P 20000530
WO 2001-US17014 W 20010525
JP 2003534377 T2 20031118 JP 2001-587767 20010525
US 2000-207918P P 20000530
WO 2001-US17014 W 20010525
US 2002004512 A1 20020110 US 2001-867309 20010529
US 6376509 B2 20020423
US 2000-207918P P 20000530

OS MARPAT 136:15253

IT **378741-82-3P 379266-73-6DP**, isomers **379266-73-6P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(melanocortin receptor agonist preparation for therapeutic use)

RN 378741-82-3 CAPLUS

CN 3-Isoquinolinecarboxamide, N-[(1R)-1-[(4-chlorophenyl)methyl]-2-[2,3,3a,4,6,7-hexahydro-2-methyl-3-oxo-3a-(phenylmethyl)-5H-pyrazolo[4,3-c]pyridin-5-yl]-2-oxoethyl]-1,2,3,4-tetrahydro-, (3R)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 378741-76-5
CMF C33 H34 Cl N5 O3

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 379266-73-6 CAPLUS
CN 2-Naphthalenecarboxamide, 1-amino-N-[(1R)-1-[(4-chlorophenyl)methyl]-2-[2,3,3a,4,6,7-hexahydro-2-methyl-3-oxo-3a-(phenylmethyl)-5H-pyrazolo[4,3-c]pyridin-5-yl]-2-oxoethyl]-1,2,3,4-tetrahydro-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 379266-73-6 CAPLUS
CN 2-Naphthalenecarboxamide, 1-amino-N-[(1R)-1-[(4-chlorophenyl)methyl]-2-[2,3,3a,4,6,7-hexahydro-2-methyl-3-oxo-3a-(phenylmethyl)-5H-pyrazolo[4,3-c]pyridin-5-yl]-2-oxoethyl]-1,2,3,4-tetrahydro-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

IT **378741-76-5 379266-96-3**
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(melanocortin receptor agonist preparation for therapeutic use)
RN 378741-76-5 CAPLUS
CN 3-Isoquinolinecarboxamide, N-[(1R)-1-[(4-chlorophenyl)methyl]-2-[2,3,3a,4,6,7-hexahydro-2-methyl-3-oxo-3a-(phenylmethyl)-5H-pyrazolo[4,3-

c]pyridin-5-yl]-2-oxoethyl]-1,2,3,4-tetrahydro-, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 379266-96-3 CAPLUS
CN 2-Naphthalenecarboxamide, 1-amino-N-[(1R)-1-[(4-chlorophenyl)methyl]-2-[2,3,3a,4,6,7-hexahydro-2-methyl-3-oxo-3a-(phenylmethyl)-5H-pyrazolo[4,3-c]pyridin-5-yl]-2-oxoethyl]-1,2,3,4-tetrahydro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **379266-72-5DP**, isomers **379266-72-5P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and reaction; melanocortin receptor agonist preparation for therapeutic use)
RN 379266-72-5 CAPLUS
CN Carbamic acid, [2-[[[(1R)-1-[(4-chlorophenyl)methyl]-2-[2,3,3a,4,6,7-hexahydro-2-methyl-3-oxo-3a-(phenylmethyl)-5H-pyrazolo[4,3-c]pyridin-5-yl]-2-oxoethyl]amino]carbonyl]-1,2,3,4-tetrahydro-1-naphthalenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 379266-72-5 CAPLUS
CN Carbamic acid, [2-[[[(1R)-1-[(4-chlorophenyl)methyl]-2-[2,3,3a,4,6,7-hexahydro-2-methyl-3-oxo-3a-(phenylmethyl)-5H-pyrazolo[4,3-c]pyridin-5-yl]-2-oxoethyl]amino]carbonyl]-1,2,3,4-tetrahydro-1-naphthalenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



GI



I

AB The invention discloses compds. and derivs. thereof which are agonists of the human melanocortin receptor(s) and, in particular, are selective agonists of the human melanocortin-4 receptor (MC-4R). They are therefore useful for the treatment, control, or prevention of diseases and disorders responsive to the activation of MC-4R, e.g. obesity, diabetes, sexual dysfunction, including erectile dysfunction and female sexual dysfunction. Preparation of e.g. I is described.

RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2000:151487 CAPLUS
DN 132:203148
TI Heterocycle-containing dipeptide compounds as growth hormone secretagogues, their preparation, compositions containing them, and their applications
IN Carpino, Philip Albert
PA Pfizer Products Inc., USA
SO Jpn. Kokai Tokkyo Koho, 94 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
PI	JP 2000072771	A2	20000307	JP 1999-234704		19990820
	JP 3486137	B2	20040113			
				US 1998-97502P	P	19980821
	US 6358951	B1	20020319	US 1999-377326		19990818
				US 1998-97502P	P	19980821
	EP 995748	A1	20000426	EP 1999-306576		19990819
	EP 995748	B1	20040331			
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO					
				US 1998-97502P	P	19980821
	AT 263168	E	20040415	AT 1999-306576		19990819
				US 1998-97502P	P	19980821
	BR 9903870	A	20001003	BR 1999-3870		19990820
				US 1998-97502P	P	19980821
	MX 9907844	A	20000331	MX 1999-7844		19990823
				US 1998-97502P	P	19980821
	US 2002045622	A1	20020418	US 2001-989040		20011121
	US 6559150	B2	20030506			
				US 1998-97502P	P	19980821
				US 1999-377326	A3	19990818
	US 2003130284	A1	20030710	US 2002-313495		20021206
	US 6686359	B2	20040203			
				US 1998-97502P	P	19980821
				US 1999-377326	A3	19990818
				US 2001-989040	A3	20011121

OS MARPAT 132:203148
IT **260357-81-1 260357-82-2 260357-83-3**
260357-84-4 260357-85-5 260357-86-6
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(preparation of heterocycle-containing amide compds. as growth hormone secretagogues and their applications)

RN 260357-81-1 CAPLUS
CN Benzamide, 3-(aminomethyl)-N-[2-[2,3,3a,4,6,7-hexahydro-2-methyl-3-oxo-3a-(phenylmethyl)-5H-pyrazolo[4,3-c]pyridin-5-yl]-2-oxo-1-[(phenylmethoxy)methyl]ethyl]- (9CI) (CA INDEX NAME)



RN 260357-82-2 CAPLUS
CN Benzamide, 3-(1-aminoethyl)-N-[2-[2,3,3a,4,6,7-hexahydro-2-methyl-3-oxo-3a-(phenylmethyl)-5H-pyrazolo[4,3-c]pyridin-5-yl]-2-oxo-1-[(phenylmethoxy)methyl]ethyl]- (9CI) (CA INDEX NAME)



RN 260357-83-3 CAPLUS
CN Benzamide, 3-(1-amino-1-methylethyl)-N-[2-[2,3,3a,4,6,7-hexahydro-2-methyl-3-oxo-3a-(phenylmethyl)-5H-pyrazolo[4,3-c]pyridin-5-yl]-2-oxo-1-[(phenylmethoxy)methyl]ethyl]- (9CI) (CA INDEX NAME)



RN 260357-84-4 CAPLUS
CN Benzamide, 3-(1-amino-1-methylethyl)-N-[2-[2,3,3a,4,6,7-hexahydro-3-oxo-3a-(phenylmethyl)-5H-pyrazolo[4,3-c]pyridin-5-yl]-2-oxo-1-[(phenylmethoxy)methyl]ethyl]- (9CI) (CA INDEX NAME)



RN 260357-85-5 CAPLUS
CN Benzamide, 3-(1-amino-1-methylethyl)-N-[2-[2,3,3a,4,6,7-hexahydro-2-methyl-3-oxo-3a-(phenylmethyl)-5H-pyrazolo[4,3-c]pyridin-5-yl]-1-(1H-indol-3-ylmethyl)-2-oxoethyl]- (9CI) (CA INDEX NAME)



RN 260357-86-6 CAPLUS
CN Benzamide, 3-(1-amino-1-methylethyl)-N-[1-[[(2,4-difluorophenyl)methoxy]methyl]-2-[2,3,3a,4,6,7-hexahydro-3-oxo-3a-(2-pyridinylmethyl)-2-(2,2,2-trifluoroethyl)-5H-pyrazolo[4,3-c]pyridin-5-yl]-2-oxoethyl]- (9CI) (CA INDEX NAME)



GI



Q



Q1



Q2



Q3



Q4

AB HET-COCR3R4NX4COR6NR7R8 [I; HET = heterocyclyl Q, Q1, Q2, Q3, Q4 (definitions for variants are given); R3 = certain (un)substituted ring systems (A1), alkyl, A1-alkyl, etc.; R4 = H, alkyl, cycloalkyl or CR3R4 = a ring system; X4 = H, alkyl, or X4 and R4 form a ring; R6 = linking group containing O, S, CH:CH (hetero)arylene; R7, R8 = H, (un)substituted alkyl or R7R8N forms a ring], mixts. of their stereoisomers, diastereomerically or enantiomerically pure isomers, their pharmaceutically acceptable salts, or their prodrugs are claimed. I are growth hormone secretagogues and are useful for increasing the level of endogenous growth hormone, treating musculoskeletal fragility such as osteoporosis in combination with selective estrogen receptor modulators, treating insulin resistance, enhancing milk production, promoting piglet growth, etc. (preparation given) showed dose-related lowering of plasma glucose and/or insulin levels when administered to female rat of three months, which is consistent with an improvement in glycemic control and insulin sensitivity. The treatment was also associated with trends for decreased plasma lactate, cholesterol, and triglyceride levels, which is also consistent with an improvement in lipid profile and metabolic control as a result of improved insulin sensitivity incurred by this treatment.

=> log y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	17.90	173.53
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-2.10	-2.10